Search

VISION 2020 LINKS Programme: Reviewing the first ten years and announcing the new diabetic retinopathy initiative

The VISION 2020 LINKS Programme celebrates its 10th anniversary next month. Over the past decade it has achieved its objective of building capacity for eye care in developing countries, particularly in Africa, by establishing long-term training partnerships between institutions, known...

The invisible touch: a VISION 2020 LINK with Indonesia

Indonesia’s population, the world’s fourth largest, is spread across 6,000 inhabited islands. Whilst some areas (e.g. Kalimantan, Papua) are relatively sparsely populated, Java is the world’s most densely populated island, with twice the population of the UK in half the...

Retinoblastoma management update (part 2): treatment, screening and surveillance, long-term follow-up and new developments

Retinoblastoma treatment requires significant multidisciplinary input, but early detection through raising awareness remains key to improving outcomes. In the second article of a two-part series, Manoj Parulekar discusses retinoblastoma management, screening and research. This article has been published in two...

Retinoblastoma management update (part 1): clinical features, diagnosis and genetics

The first of a two part series, this article will discuss the clinical features, diagnosis and genetic aspects of retinoblastoma. Manoj Parulekar is based at Birmingham Children’s Hospital, one of the two designated national retinoblastoma and paediatric ocular oncology treatment...

Sickle cell eye disease: an overview of vitreoretinal complications and their surgical management

Sickle cell disease is the most common genetic disorder worldwide and is associated with lifelong anaemia, intermittent pain and multi-organ morbidity. Ocular involvement can be associated with significant visual impairment due to the complications of proliferative sickle retinopathy (PSR). Occasionally...

What’s new in wet AMD papers?

Paper presentations on neovascular (‘wet’) age-related macular degeneration (AMD) from the 16th European Society of Retina Specialists Congress, Copenhagen, September 2016, outline recent research directions evaluating the impact of vision loss on key health domains, patient preferences in the process...

More sensitive visual acuity test for age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...

The David J Apple International Laboratory for Ocular Pathology – a legacy of pioneering IOL research

David Apple and Gerd Auffarth. The Apple Lab at the David J Apple Center for Vision Research in Heidelberg is a thriving international laboratory for research into intraocular devices. The lab continues the work of David J Apple, a world-renowned...

Surgical options for the treatment of hyperopia

The modern refractive surgeon has a variety of options available to treat patients with hyperopia who wish to be independent of spectacles and contact lenses. Unlike in low myopia where presbyopic patients may have the ability to see well for...

Principles of management

Whatever section of pathology is to blame and wherever it strikes, the aim of treatment is always the same. Find the cause if you can. Establish the effects of the cause. Halt the pathological process if you can. Reverse its...

EU: is it time to leave and embrace the world?

Should the United Kingdom remain a member of the European Union (EU) or leave? It’s a big decision involving some complex issues, and there’s no doubt the EU will continue to change. Ipsos MORI’s monthly EU voting intention poll published...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...